Discontinued — last reported Q3 '22
Year-over-year, this metric grew by 29680.0%, from $5.00M to $1.49B. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 34.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.00M | $7.00M | $590.00M | -$1.00M | $100.00M | $7.00M | $649.00M | $34.00M | $0.00 | $5.00M | $1.29B | $44.00M | $22.00M | $0.00 | $5.00M | $478.00M | $1.00M | $0.00 | $1.49B |
| QoQ Change | — | +250.0% | >999% | -100.2% | >999% | -93.0% | >999% | -94.8% | -100.0% | — | >999% | -96.6% | -50.0% | -100.0% | — | >999% | -99.8% | -100.0% | — |
| YoY Change | — | — | — | — | >999% | +0.0% | +10.0% | >999% | -100.0% | -28.6% | +98.8% | +29.4% | — | -100.0% | -99.6% | +986.4% | -95.5% | — | >999% |